Enveric Biosciences EBIT

The latest EBIT for ENVB is $-8.7M as of June 2026. That compares with $-10M in the prior-year period — up 12.4% year over year. That is below the Technology sector average of $14T. Investors often review this figure alongside Enveric Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, ENVB's EBIT moved from $-10M to $-8.7M — a 12.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Enveric Biosciences's operating scale or balance-sheet position.

Against Technology companies, ENVB currently prints $-8.7M for EBIT, while the sector average sits near $14T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Enveric Biosciences's growth, margins, and balance sheet.

A EBIT figure of $-8.7M for ENVB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Technology average is about $14T. Explore the charts below for those layers of context.

After noting ENVB's EBIT ($-8.7M), review year-over-year change from $-10M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.